Inspira Technologies Enters Strategic OEM Agreement With Terumo Cardiovascular

December 28, 2022—Inspira Technologies OXY B.H.N. Ltd., an Israel-based company focused on respiratory support technology, announced that it has signed an exclusive original equipment manufacturing (OEM) agreement with Terumo Cardiovascular, a division of the global Terumo Corporation. Terumo Cardiovascular has expertise in the field of oxygenation systems, heart-lung machines, and monitoring systems, noted Inspira’s press release.

According to the company, the agreement provides for Terumo to manufacture a flow mechanism that is intended to be integrated into Inspira Technologies’ products for use in the extracorporeal circulation of the blood during the oxygenation process. This may also include integration into the Inspira Art system, which is designed to introduce a new mode of acute respiratory care by boosting oxygen saturation levels in minutes using small volumes of blood.

The Inspira Art system with the company’s “augmented respiration technology” is designed to treat patients by rebalancing their oxygen saturation levels while they are awake and breathing spontaneously, reducing the need for invasive mechanical ventilation.

Inspira Technologies’ products have not yet been tested or used in humans and have not been approved by any regulatory entity, advised the company.

Joe Hayon, Inspira Technologies’ Cofounder and President, stated in the press release, “This is a very important agreement for the company, and we believe that it is in line with our strategy towards developing collaborations with the largest medical device companies to join in on our journey to market.”